Abstracts tagged "glucocorticoids"

Abstract Number: 1665 • 2019 ACR/ARP Annual Meeting
Glucocorticoids in Incident ANCA-Associated Vasculitis (AAV) Patients – A Study of Routine Clinical Practice in the EU Demonstrates Prolonged Use and Temporal Relationship to Adverse Events and Infections
Dieter Goette¹ and Peter Rutherford ¹, ¹Vifor Pharma, Zurich, Zurich, Switzerland
Background/Purpose: AAV is a severe systemic vasculitis and rapid induction of remission is essential and high dose glucocorticoids (GC) are part of standard of care.…
Abstract Number: 1666 • 2019 ACR/ARP Annual Meeting
Maintenance Treatment in ANCA Associated Vasculitis in Real World Clinical Practice – Burden of Disease, Use of Glucocorticoids and Impact on Patient Functional Status Remain Major Problems
Dieter Goette¹ and Peter Rutherford ¹, ¹Vifor Pharma, Zurich, Zurich, Switzerland
Background/Purpose: After successful remission induction AAV is a relapsing remitting long term condition and patients are at risk of organ damage from both active AAV…
Abstract Number: L18 • 2018 ACR/ARHP Annual Meeting
A Randomized Controlled 24-Week Trial Evaluating the Safety and Efficacy of Blinded Tapering Versus Continuation of Long-Term Prednisone (5 mg/day) in Patients with Rheumatoid Arthritis Who Achieved Low Disease Activity or Remission on Tocilizumab
Gerd R. Burmester¹, Frank Buttgereit¹, Corrado Bernasconi², Jose Maria Alvaro-Gracia³, Nidia Castro², Maxime Dougados⁴, Cem Gabay⁵, Jacob van Laar⁶, J. Michael Nebesky², Attila Pethö-Schramm², Carlo Salvarani⁷, Marc Y. Donath⁸ and Markus R. John², ¹Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany, ²F. Hoffmann-La Roche, Basel, Switzerland, ³Hospital Universitario de La Princesa IIS-IP, Madrid, Spain, ⁴Université Paris-Descartes, Paris, France, ⁵University Hospitals of Geneva, Geneva, Switzerland, ⁶University Medical Centre Utrecht, Utrecht, Netherlands, ⁷Università de Modena e Reggio Emilia, Modena, Italy, ⁸University Hospital Basel, Basel, Switzerland
Background/Purpose: Guidelines recommend low-dose, short-duration glucocorticoid (GC) treatment for RA,1,2 but long-term use, especially at prednisone-equivalent doses >5 mg/d, should be avoided.2 Many patients (pts)…
Abstract Number: 2300 • 2018 ACR/ARHP Annual Meeting
Compliance with Screening and Supplementation Guidelines for Glucocorticoid-Induced Osteoporosis, How Bad Did We Do This Time?
John Zawidniak¹ and John Waterman², ¹Rheumatology, University of Connecticut, Farmington, CT, ²Rheumatology, Connecticut VA Healthcare System, Newington, CT
Background/Purpose: Glucocorticoid-induced osteoporosis (GIOP) is a well-established and well-studied phenomenon that is a sequela of the treatment of many inflammatory diseases. Many studies over the…
Abstract Number: 2319 • 2018 ACR/ARHP Annual Meeting
Adherence to Guideline Recommendations for Screening and Treatment of Glucocorticoid Induced Osteoporosis in Patients with Rheumatoid Arthritis on Long Term Glucocorticoid Therapy at a Tertiary Care Center
Patrick Webster¹ and Tarun S. Sharma², ¹Internal Medicine, Allegheny Health Network, Pittsburgh, PA, ²Rheumatology, Lupus Center of Excellence, Allegheny Health Network, Pittsburgh, PA
Background/Purpose: Glucocorticoid induced osteoporosis (GIOP) is an under-recognized and under-treated condition. Many long-term glucocorticoid (GC) users never receive therapy to prevent bone loss or are…
Abstract Number: 2327 • 2018 ACR/ARHP Annual Meeting
To Screen or Not to Screen?Dexa Ordering Patterns in SLE Patients Who Take Systemic Glucocorticoids
Sara Baig¹, Smarika Sapkota², Anna K. Shmagel³, Parastoo Fazeli⁴, Jeremiah Menk¹ and Ann Marie O'Connell⁵, ¹University of Minnesota, Minneapolis, MN, ²Division of General Internal Medicine, University of Minnesota, Minneapolis, MN, ³Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, ⁴Rheumatology, University of Minnesota, Minneapolis, MN, ⁵University of Minnesota, MInneapolis, MN
Background/Purpose: High doses of glucocorticoids (GC) are often used in the treatment of Systemic Lupus Erythematous (SLE), however, studies suggest that SLE patients do not…
Abstract Number: 2339 • 2018 ACR/ARHP Annual Meeting
The Patient’s Perspective of Glucocorticoid Use: A Systematic Literature Review of Quantitative and Qualitative Studies
Jonathan Cheah^1,2, Joanna Robson^3,4, Rachel Black^5,6, Susan M. Goodman^7,8, Susan Lester^9,10, Sarah Mackie¹¹ and Catherine Hill^6,12, ¹Medicine, Hospital for Special Surgery, New York, NY, ²Medicine, Weill Cornell Medicine, New York, NY, ³Faculty of Health and Applied Science, University of the West of England, Bristol, United Kingdom, ⁴School of Clinical Sciences, University of Bristol, Bristol, United Kingdom, ⁵Rheumatology, Royal Adelaide Hospital, Adelaide, Australia, ⁶Medicine, The University of Adelaide, Adelaide, Australia, ⁷Rheumatology, Weill Cornell Medicine, New York, NY, ⁸Hospital for Special Surgery, New York, NY, ⁹Rheumatology Unit, The Queen Elizabeth Hospital, Adelaide, Australia, ¹⁰Discipline of Medicine, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, Australia, ¹¹NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ¹²The Queen Elizabeth Hospital, Adelaide, Australia
Background/Purpose: Glucocorticoids (GCs) remain widely used and have well documented adverse effects. However, the impact of these adverse effects from the perspective of the patient,…
Abstract Number: 2340 • 2018 ACR/ARHP Annual Meeting
The Impact of Chronic Glucocorticoid Use Amongst Patients with Rheumatoid Arthritis: A Qualitative Study
Jonathan Cheah^1,2, Sarah Young³, Susan M. Goodman^4,5, Catherine Hill^6,7, Susan Beard⁸, Pamela Richards⁹, Sarah Mackie¹⁰, Joanna Robson^11,12 and Iris Navarro-Millán^5,13, ¹Medicine, Hospital for Special Surgery, New York, NY, ²Medicine, Weill Cornell Medicine, New York, NY, ³Binghamton University, Binghamton, NY, ⁴Rheumatology, Weill Cornell Medicine, New York, NY, ⁵Hospital for Special Surgery, New York, NY, ⁶The Queen Elizabeth Hospital, Adelaide, Australia, ⁷Medicine, The University of Adelaide, Adelaide, Australia, ⁸Patient Research Partner, Adelaide, Australia, ⁹Patient Research Partner, Bristol, United Kingdom, ¹⁰NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ¹¹Faculty of Health and Applied Science, University of the West of England, Bristol, United Kingdom, ¹²School of Clinical Sciences, University of Bristol, Bristol, United Kingdom, ¹³Weill Cornell Medicine, New York, NY
Background/Purpose: Glucocorticoids (GCs) have well documented adverse effects. However, the absolute risk and importance of these effects have not been well documented from the perspective…
Abstract Number: 534 • 2018 ACR/ARHP Annual Meeting
Increased Insulin Resistance and Impaired Beta-Cell Function in Patients with Rheumatoid Arthritis: The Role of Glucocorticoid Therapy?
Gorica Ristic¹, Vesna Subota², Dejana Stanisavljevic³, Branislava Glisic¹, Milan Petronijevic¹ and Dusan Stefanovic¹, ¹Department of Rheumatology and Clinical Immunology, Military Medical Academy, Belgrade, Serbia, ²Institute of Medical Biochemistry, Military Medical Academy, Belgrade, Serbia, ³Institute of Medical Statistics, Belgrade University School of Medicine, Belgrade, Serbia
Background/Purpose: Increased insulin resistance and impaired β-cell function have been demonstrated in rheumatoid arthritis (RA). The aim of the study was to analyze the association…
Abstract Number: 2637 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine Improves Disease Activity and Allows Reduction of Corticosteroid Dose Regardless of Background Treatment in Japanese Patients with Systemic Lupus Erythematosus
Hironari Hanaoka, Harunobu Iida, Tomofumi Kiyokawa, Yukiko Takakuwa and Kimito Kawahata, Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Hydroxychloroquine (HCQ) was not approved in Japan until 2015 and its therapeutic potential remains poorly understood in the population. In this study, we evaluated…
Abstract Number: 545 • 2018 ACR/ARHP Annual Meeting
How to Treat Rheumatoid Arthritis Patients When Methotrexate Has Failed? Results from the Meteor Registry
Sytske Anne Bergstra¹, Lai-Ling Winchow², Elizabeth Murphy³, Arvind Chopra⁴, Karen Salomon-Escoto⁵, João E. Fonseca⁶, Cornelia F. Allaart¹ and Robert B.M. Landewé⁷, ¹Department of Rheumatology, LUMC, Leiden, Netherlands, ²University of the Witwatersrand, Johannesburg, South Africa, ³University Hospital Wishaw, Scotland, Wishaw, United Kingdom, ⁴Center for Rheumatic Diseases, Pune, India, ⁵University of Massachusetts Medical School, Rheumatology Center, UMass Memorial Medical Center, Worcester, MA, ⁶Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, CHLN, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, ⁷Amsterdam Rheumatology & Immunology Center | Zuyderland Medical Center, Heerlen, Netherlands
Background/Purpose: After failure of initial methotrexate (MTX) treatment in rheumatoid arthritis (RA) patients, various treatment options can be considered. To date, evidence about the preferred…
Abstract Number: 2639 • 2018 ACR/ARHP Annual Meeting
Bone Mineral Density Is Not Associated with Osteoporotic Fractures in Premenopausal Women and Men < 50 Years Old with Systemic Lupus Erythematosus
Tracy Driver¹, Maureen A. McMahon², Betty Tsao³ and Jennifer M. Grossman⁴, ¹Medicine, Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²UCLA David Geffen School of Medicine, Los Angeles, CA, ³Medical University of South Carolina, Charleston, SC, ⁴Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Osteoporosis is common in patients with systemic lupus erythematosus (SLE). Guidelines for the treatment and prevention of glucocorticoid induced osteoporosis (GIOP) are detailed for…
Abstract Number: 547 • 2018 ACR/ARHP Annual Meeting
Corticosteroid Bridging Strategies with Methotrexate Monotherapy in Early Rheumatoid and Undifferentiated Arthritis; A Comparison of Efficacy and Toxicity in 2 Clinical Trials
Elisabeth G. Brilman¹, Joy A. van der Pol¹, Pascal HP de Jong^2,3, Angelique EAM Weel^2,3, JMW Hazes², Tom W.J. Huizinga⁴ and Cornelia F. Allaart¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Erasmus Medical Center Rotterdam, Rotterdam, Netherlands, ³Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: What is the optimal glucocorticoid (GC) bridging therapy with MTX monotherapy in early arthritis? Methods: In trial A, early RA and UA (arthritis in ≥1…
Abstract Number: 2679 • 2018 ACR/ARHP Annual Meeting
Glucocorticoids Withdrawal in Systemic Lupus Erythematosus: Are Remission and Low Disease Activity Reliable Starting Points for Stopping Therapy? a Real-Life Experience
Viola Signorini, Chiara Tani, Elena Elefante, Chiara Stagnaro, Linda Carli and Marta Mosca, Rheumatology Unit, University of Pisa, Pisa, Italy
Background/Purpose: Glucocorticoids (GC) are a cornerstone of the treatment of Systemic Lupus Erythematosus (SLE); however, a significant organ damage is associated with long-term GC use…
Abstract Number: 709 • 2018 ACR/ARHP Annual Meeting
Differential Characteristics of Lupus Psychosis and Steroid Psychosis
Shunsei Hirohata^1,2,3, Yoshinori Kanai⁴, Akiko Mitsuo⁵, Yoshiaki Tokano⁴ and Hiroshi Hashimoto⁴, ¹Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ²Nobuhira Hospital, Tatsuno, Japan, ³Kitasato University School of Medicine, Sagamihara, Japan, ⁴Juntendo University School of Medicine, Tokyo, Japan, ⁵Rheumatology, National Hospital Organization Disaster Medical Center, Tokyo, Japan
Background/Purpose: Psychiatric manifestations are relatively common in patients with systemic lupus erythematosus (SLE). Since there are a number of factors causing psychiatric manifestations other than…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].